Warning! GuruFocus detected
7 Medium warning signs
with PBV.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Prestige Consumer Healthcare Inc
NAICS : 325412
SIC : 2834
ISIN : US74112D1019
Description
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | 2.85 | |||||
| Interest Coverage | 6.34 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.98 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.4 | |||||
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | 9.1 | |||||
| 3-Year FCF Growth Rate | 4.2 | |||||
| 3-Year Book Growth Rate | 6.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 6.08 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 1.75 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.59 | |||||
| 9-Day RSI | 30.06 | |||||
| 14-Day RSI | 33.67 | |||||
| 3-1 Month Momentum % | 11.43 | |||||
| 6-1 Month Momentum % | 25.81 | |||||
| 12-1 Month Momentum % | 22.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.68 | |||||
| Quick Ratio | 2.2 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 108.65 | |||||
| Days Sales Outstanding | 56.26 | |||||
| Days Payable | 24.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | 6.3 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.11 | |||||
| Operating Margin % | 29.56 | |||||
| Net Margin % | 19.13 | |||||
| FCF Margin % | 22.22 | |||||
| ROE % | 12.65 | |||||
| ROA % | 6.44 | |||||
| ROIC % | 8.02 | |||||
| 3-Year ROIIC % | -14.34 | |||||
| ROC (Joel Greenblatt) % | 105.16 | |||||
| ROCE % | 10.27 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.23 | |||||
| Forward PE Ratio | 16.18 | |||||
| PE Ratio without NRI | 19.05 | |||||
| Shiller PE Ratio | 27.5 | |||||
| Price-to-Owner-Earnings | 18.31 | |||||
| PS Ratio | 3.68 | |||||
| PB Ratio | 2.28 | |||||
| Price-to-Free-Cash-Flow | 16.55 | |||||
| Price-to-Operating-Cash-Flow | 16.05 | |||||
| EV-to-EBIT | 15.3 | |||||
| EV-to-Forward-EBIT | 14.31 | |||||
| EV-to-EBITDA | 13.99 | |||||
| EV-to-Forward-EBITDA | 13.31 | |||||
| EV-to-Revenue | 4.51 | |||||
| EV-to-Forward-Revenue | 4.36 | |||||
| EV-to-FCF | 20.28 | |||||
| Price-to-GF-Value | 1.3 | |||||
| Price-to-Projected-FCF | 1.15 | |||||
| Price-to-Median-PS-Value | 1.34 | |||||
| Earnings Yield (Greenblatt) % | 6.54 | |||||
| FCF Yield % | 6.11 | |||||
| Forward Rate of Return (Yacktman) % | -17.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Prestige Consumer Healthcare Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,035.95 | ||
| EPS (TTM) (€) | 3.959 | ||
| Beta | 0.34 | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 1.18 | ||
| Volatility % | 28.74 | ||
| 14-Day RSI | 33.67 | ||
| 14-Day ATR (€) | 1.844173 | ||
| 20-Day SMA (€) | 75.7 | ||
| 12-1 Month Momentum % | 22.83 | ||
| 52-Week Range (€) | 57.5 - 85 | ||
| Shares Outstanding (Mil) | 49.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prestige Consumer Healthcare Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prestige Consumer Healthcare Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Prestige Consumer Healthcare Inc Frequently Asked Questions
What is Prestige Consumer Healthcare Inc(FRA:PBV)'s stock price today?
The current price of FRA:PBV is €70.00. The 52 week high of FRA:PBV is €85.00 and 52 week low is €57.50.
When is next earnings date of Prestige Consumer Healthcare Inc(FRA:PBV)?
The next earnings date of Prestige Consumer Healthcare Inc(FRA:PBV) is 2025-05-08.
Does Prestige Consumer Healthcare Inc(FRA:PBV) pay dividends? If so, how much?
Prestige Consumer Healthcare Inc(FRA:PBV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers